您的位置: 首页 > 2026年1月 第57卷 第1期 > 文字全文
2023年7月 第38卷 第7期11
目录

LAMP3 基因表达与肾癌之间的因果关系:一项基于孟德尔随机化分析的研究

Causal relationship between LAMP3 gene expression and renal cancer:A Mendelian randomization analysis

来源期刊: 广州医药 | 88-94 发布时间:2026-01-20 收稿时间:2026/2/6 23:01:20 阅读量:27
作者:
关键词:
孟德尔随机化LAMP3肾癌
Mendelian randomizationLAMP3renal cancer
DOI:
10. 20223 / j. cnki. 1000-8535. 2026. 01. 013
收稿时间:
2025-02-19 
修订日期:
 
接收日期:
 
引用总数:
0  
       目的   探讨溶酶体相关膜蛋白3(LAMP3)与肾癌发病风险之间的因果关系,为肾癌的分子致病机制提供新的理论依据。方法   基于全基因组关联研究(GWAS)数据,采用孟德尔随机化分析方法,评估LAMP3基因表达与肾癌的因果关系。并通过GEPIA2分析LAMP3表达对肾癌总体生存期(OS)及无病生存期(DFS)的关系。结果  LAMP3基因变异与肾癌风险呈正相关,提示LAMP3的表达可能增加肾癌的发病风险。此外,GEPIA2分析进一步显示,LAMP3的高表达与肾癌患者的低总体生存期(OS)及无病生存期(DFS)显著相关。结论   本研究通过孟德尔随机化分析探讨了LAMP3基因表达与肾癌的因果关系,结果表明LAMP3可能是肾癌的潜在致病因子,并与肾癌预后相关。这为肾癌的分子致病机制研究提供了重要的理论依据,并为未来的生物标志物和靶向治疗策略的开发提供了新的思路。
        Objective  To investigate the causal  relationship  between LAMP3 expression and  renal cancer  risk  using Mendelian randomization analysis,providing a theoretical basis for understanding the molecular mechanisms underlying renal cancer.Methods  This study utilized data from genome-wide association studies(GWAS)and employed Mendelian randomization analysis to assess the causal relationship between LAMP3 gene expression and renal cancer.Additionally,GEPIA2 was used to examine the association between LAMP3 expression and overall survival(OS)and disease-free survival(DFS)in renal cancer patients.Results  Variants in the LAMP3 gene were positively correlated with renal cancer risk,suggesting that LAMP3 expression may increase the likelihood of developing renal cancer.Furthermore,GEPIA2 analysis  revealed that high expression of LAMP3 was significantly associated with lower OS and DFS in renal cancer patients.Conclusions  This study explored the causal  relationship between LAMP3 gene expression and renal cancer through Mendelian randomization analysis.The results indicate that LAMP3 may be a potential pathogenic factor in renal cancer and is associated with poor prognosis.These findings provide important theoretical insights into the molecular mechanisms of  renal cancer and offer new perspectives for the development of biomarkers and targeted therapeutic strategies in the future.
       肾癌是全球最常见的泌尿系统恶性肿瘤之一,也是癌症相关死亡的主要原因之一[1]。根据全球癌症统计数据,肾癌的发病率和病死率近年来呈上升趋势[2]。肾癌具有高度异质性,常见的亚型包括肾透明细胞癌、乳头状肾细胞癌和嫌色细胞癌。
       目前许多遗传学研究集中在“肾脏恶性肿瘤”这一广泛定义(即排除肾盂恶性肿瘤及其他癌症),并未对具体亚型进行深入分析[3]。这种全覆盖的分析方法虽然有助于评估肾癌的总体遗传风险因素,但可能忽视了各亚型的特异性分子机制。因此,基于现有数据我们需探索普遍适用的生物标志物及其致病机制。
       溶酶体相关膜糖蛋白3(lysosomal-associated membrane protein 3,LAMP3)是一种定位于溶酶体和内体膜的糖基化蛋白,参与细胞代谢调节、溶酶体功能维持和细胞应激反应[4]。近年来,LAMP3被发现与乳腺癌、宫颈癌和肺癌等多种恶性肿瘤密切相关,其高表达通常与肿瘤的侵袭性增强和治疗耐药性相关[5-7]
       现阶段对LAMP3在肾癌中的作用研究仍较少,尚不清楚其是为肾癌的关键驱动因子,还是仅伴随癌症进展的表型标志物。尽管现有的观察性研究为LAMP3与肿瘤的关系提供了初步证据,但因果推断仍受到混杂因素和反向因果偏倚的影响。孟德尔随机化(Mendelian randomization,MR)是一种基于遗传变异的因果推断方法,通过利用在减数分裂过程中随机分配的遗传变异(如单核苷酸多态性,single nucleotide polymorphism,SNP),评估暴露与结局之间的因果关系[8]。由于基因型在受孕时已确定,其分布不受环境因素或疾病状态的影响,MR能有效降低传统观察性研究中的混杂偏倚,为复杂疾病的因果研究提供可靠的工具[9]
       本研究基于“肾脏恶性肿瘤,排除肾盂恶性肿瘤”的GWAS数据,采用孟德尔随机化分析方法,系统评估LAMP3与肾癌总体发病风险之间的潜在因果关系。研究结果有望为揭示肾癌的分子致病机制提供理论依据,并为新型诊断与治疗靶点的开发奠定基础。

1  资料与方法

1.1 研究设计

       本研究采用两样本孟德尔随机化分析方法,探讨LAMP3与肾癌患病风险之间的因果关系。所有分析严格遵循孟德尔随机化报告指南(STROBE-MR)的规范[10]。研究数据来自公开的全基因组关联研究(Genome-Wide Association Study,GWAS)数据库,通过筛选与LAMP3基因表达水平相关SNP,作为工具变量(instrumental variables,IVs),以“肾脏恶性肿瘤,肾盂除外”作为研究结局变量。
       为了确保所选SNP满足孟德尔随机化的三个核心假设[11],即:(1)SNP与暴露因素(LAMP3基因表达)高度相关;(2)SNP与任何潜在的混杂因素无关;(3)SNP仅通过暴露因素对结局变量肾癌产生影响,不直接影响结局变量。

1.2 数据来源

       本研究所用GWAS数据来源于公开的IEU Open GWAS项目[12](https://gwas.mrcieu.ac.uk)。暴露因素LAMP3(prot-a-1698)的GWAS数据来自GTEx项目(The Genotype-Tissue Expression Project),该项目提供了多种组织中基因表达与遗传变异的关联信息[13],并选取了与LAMP3在肾组织中的表达水平显著相关的SNP。研究结局(肾癌)的GWAS数据来自一项涵盖“肾脏恶性肿瘤(肾盂癌除外)”的欧洲血统个体的大规模全基因组关联研究[14]

1.3 工具变量的选取

       为探讨LAMP3基因表达与肾癌之间的因果关系,本研究严格筛选了工具变量SNP,具体标准如下[15]:(1)工具变量与暴露因素(LAMP3基因表达水平)高度相关,筛选P值小于5×10-8SNP;(2)设置连锁不平衡参数为r 2 <0.01,并将区域宽度设置为10 000 kb,以避免连锁不平衡带来的偏倚;(3)使用F统计量评估工具变量的效能,F值小于10通常提示可能存在弱工具变量偏倚,需剔除低效能SNP。

1.4 孟德尔随机化分析与质量控制

      本研究采用逆方差加权法(inverse  variance weighted,IVW)作为主要的孟德尔随机化分析方法[16],并结合其他方法(如加权中位数法、MR-Egger回归)进行稳健性验证。结果以比值比(odds ratio,OR)及其95%置信区间(confidence interval,CI)表示。
       为评估分析结果的稳健性与可靠性,本研究进行了详细的质量控制。通过MR-Egger法截距项评估多效性[17],使用Cochran’s Q检验评估异质性,并通过Leave-One-Out敏感性分析检查单个SNP对结果的影响[18]。所有统计分析均在R Studio 4.3.2软件中完成,主要使用TwoSampleMR[19]具包。

1.5 GEPIA2分析

       GEPIA2(http://gepia.cancer-pku.cn/index.html)是一个基于癌症基因组图谱(The  Cancer Genome Atlas,TCGA)和基因型-组织表达(genotype-tissue expression,GTEx)项目RNA测序数据的在线分析平台[20]。本研究利用GEPIA2分析工具,评估LAMP3基因表达与肾癌中的总体生存期(overall survival,OS)和无病生存期(disease-free survival,DFS)的相关性,以进一步验证其临床意义。

2  结 果

2.1 工具变量的选择与效能

      本研究选择了多个与LAMP3基因表达相关的SNP作为工具变量,以评估LAMP3在肾癌发病风险中的因果效应。所有选定的SNP均通过了效能检验,F统计量均大于10,表明这些SNP为强工具变量,适合用于孟德尔随机化分析,不易受到弱工具变量的影响。

2.2 LAMP3与肾癌风险的因果关系分析

       LAMP3与肾癌风险的因果关系IVW分析,LAMP3基因变异与肾癌风险呈正相关,b=0.25(P<0.05),提示LAMP3的表达可能增加肾癌的患病风险(表1)。该结果在不同SNP的分析中得到了验证。

表1 LAMP3与肾脏恶性肿瘤(肾盂癌除外)的两样本孟德尔随机化分析结果

暴露

结局

方法

nsnp

b

se

P

LAMP3

 

肾脏恶性肿瘤(肾盂癌除外)

 

MR Egger

13

0.147

0.312

0.645

Weighted median

13

0.208

0.161

0.195

Inverse variance weighted

13

0.250

0.125

0.047

Simple mode

13

0.128

0.250

0.618

Weighted mode

13

0.128

0.241

0.604

       散点图和森林图(图1和图2)显示,LAMP3基因变异与肾癌风险之间的关系较为一致,且大多数SNP均表现出一致的方向性效应。
20260209142456_4110.png
图 1  LAMP3 工具变量的MR效应散点图
20260209142521_5936.png
图 2   森林图

2.3 异质性与多效性分析

       为评估不同SNP之间的异质性,我们使用了Cochran’s Q检验。结果显示,Q统计量为12.34P=0.09),未发现显著的异质性,表明LAMP3相关SNP作为工具变量的效果较为一致。

2.4 敏感性分析

       通过留一法敏感性分析(见图3),进一步验证了分析结果的稳健性。结果表明,去除任何单个SNP对总体分析结果影响较小,支持本研究的结论在不同工具变量下的稳定性。
20260209142556_2547.png
图 3   留一法敏感性分析结果

2.5 总体生存期与无病生存期

       使用GEPIA2分析了LAMP3基因表达与肾癌(包括肾嫌色细胞、肾透明细胞癌、肾乳头状细胞癌)患者的生存期(见图4)。高LAMP3表达组的患者OS较短,与低表达组相比,其死亡风险增加(HR=1.7,P=0.000 29)。此外,LAMP3表达与DFS呈负相关,高LAMP3表达组的复发风险较高(HR=2.0,P=7.6×10-6)。Log-rank检验的P值分别为0.000 25和5×10-6,表明两组之间的差异具有统计学意义。
20260209142625_2899.png
图 4  LAMP3 基因与肾癌患者生存期的关联分析

3  讨 论

       本研究通过双样本孟德尔随机化分析,首次探讨LAMP3基因表达与肾癌发病风险之间的因果关系。本研究结果表明,LAMP3基因变异与肾癌风险呈正相关,这为LAMP3作为肾癌潜在致病因子的理论基础提供了支持。
       现阶段许多研究证实了LAMP3参与了多种恶性肿瘤发生发展,例如在食管癌、结直肠癌和乳腺癌等肿瘤中,LAMP3的高表达与肿瘤的侵袭性、转移及患者预后相关[21-23]。在泌尿系统肿瘤中,有研究发现LAMP3与TP53表达之间存在显著相关性,提示LAMP3可能与前列腺癌的基因改变相关[24-25]。此外,有研究显示,LAMP3+DC在膀胱尿路上皮癌组织中显著富集,其表达包括CCL17和CCL22等细胞因子,这些因子与调节性T细胞(regulatory T cells,Tregs)膜上的CCR4结合,产生强大的趋化作用,将Tregs募集到肿瘤区域,从而抑制CD8+  T细胞的活性,抑制肿瘤免疫反[26],提示LAMP3可能作为膀胱癌治疗的潜在靶点。这些结果进一步支持了LAMP3作为肿瘤相关生物标志物的潜力。
       本研究显示,LAMP3与肾癌存在正向因果关联,并且对患者的OS和DFS均具有显著影响,提示LAMP3可能通过多途径参与肾癌的发生、发展,可能在调节细胞自噬、免疫微环境和肿瘤细胞迁移等方面发挥关键作用[27]。然而,本研究未进行性别分层分析,也未对不同肾癌病理亚型进行详细分类。需要注意的是,LAMP3可能在不同性别的患者和肾癌不同亚型中发挥不同的作用。相关研究表明,男性和女性肾癌在分子特征和免疫微环境上存在差异[28],不同病理类型的肾癌也表现出不同的免疫微环境[29]。因此,未来研究应进一步探讨LAMP3在不同性别和肾癌亚型患者中的表达差异及其致病机制,为个体化治疗提供依据。
       本研究的局限性在于GWAS数据库中的样本主要来自欧洲人群,缺乏其他人群的数据。此外,研究中使用的SNP工具变量的选择基于基因表达的相关数据,但肾癌的具体分型及其与LAMP3基因变异的关系尚未得到深入研究。未来的研究应采集更多来自不同种族的样本数据,并结合不同性别和肾癌亚型的具体分型数据,进行基因分层分析,以进一步验证LAMP3与肾癌的因果关系。
       未来的研究应致力于探索LAMP3在肾癌中的具体作用机制,并通过临床样本验证其作为生物标志物和靶向治疗靶点的临床价值。同时,随着单细胞RNA测序技术的发展,深入分析LAMP3在不同肾癌亚型中的作用及其在肿瘤微环境中的功能,将有助于我们更全面地理解其致病机制。
1、胡伊凌,张文戈,陈远帆,等.癌症患者生命质量测定量表体系之肾癌量表(QLICP-REV2.0)的条目筛选[J].广州医药,2025,56(1):77-81.胡伊凌,张文戈,陈远帆,等.癌症患者生命质量测定量表体系之肾癌量表(QLICP-REV2.0)的条目筛选[J].广州医药,2025,56(1):77-81.
2、SUNG%E2%80%83H%EF%BC%8CFERLAY%E2%80%83J%EF%BC%8CSIEGEL%E2%80%83R%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8EGlobal%E2%80%83%0Acancer%E2%80%83statistics%E2%80%832020%EF%BC%9AGLOBOCAN%E2%80%83%20estimates%E2%80%83%20of%E2%80%83%0Aincidence%E2%80%83and%E2%80%83mortality%E2%80%83worldwide%E2%80%83for%E2%80%83%2036%E2%80%83cancers%E2%80%83in%E2%80%83%0A185%E2%80%83countries%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECA%E2%80%83Cancer%E2%80%83J%E2%80%83Clin%EF%BC%8C2021%EF%BC%8C71%0A%EF%BC%883%EF%BC%89%EF%BC%9A209-249%EF%BC%8ESUNG%E2%80%83H%EF%BC%8CFERLAY%E2%80%83J%EF%BC%8CSIEGEL%E2%80%83R%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8EGlobal%E2%80%83%0Acancer%E2%80%83statistics%E2%80%832020%EF%BC%9AGLOBOCAN%E2%80%83%20estimates%E2%80%83%20of%E2%80%83%0Aincidence%E2%80%83and%E2%80%83mortality%E2%80%83worldwide%E2%80%83for%E2%80%83%2036%E2%80%83cancers%E2%80%83in%E2%80%83%0A185%E2%80%83countries%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECA%E2%80%83Cancer%E2%80%83J%E2%80%83Clin%EF%BC%8C2021%EF%BC%8C71%0A%EF%BC%883%EF%BC%89%EF%BC%9A209-249%EF%BC%8E
3、SCELO%E2%80%83G%EF%BC%8CLAROSE%E2%80%83T%E2%80%83L%EF%BC%8EEpidemiology%E2%80%83%20and%E2%80%83%20risk%E2%80%83%0Afactors%E2%80%83for%E2%80%83kidney%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Clin%E2%80%83Oncol%EF%BC%8C2018%EF%BC%8C%0A36%EF%BC%8836%EF%BC%89%EF%BC%9AJCO2018791905%EF%BC%8ESCELO%E2%80%83G%EF%BC%8CLAROSE%E2%80%83T%E2%80%83L%EF%BC%8EEpidemiology%E2%80%83%20and%E2%80%83%20risk%E2%80%83%0Afactors%E2%80%83for%E2%80%83kidney%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Clin%E2%80%83Oncol%EF%BC%8C2018%EF%BC%8C%0A36%EF%BC%8836%EF%BC%89%EF%BC%9AJCO2018791905%EF%BC%8E
4、TANAKA%E2%80%83T%EF%BC%8CWARNER%E2%80%83B%E2%80%83M%EF%BC%8CMICHAEL%E2%80%83D%E2%80%83G%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ALAMP3%E2%80%83inhibits%E2%80%83autophagy%E2%80%83and%E2%80%83contributes%E2%80%83to%E2%80%83cell%E2%80%83death%E2%80%83%0Aby%E2%80%83lysosomal%E2%80%83membrane%E2%80%83permeabilization%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AAutophagy%EF%BC%8C2022%EF%BC%8C18%EF%BC%887%EF%BC%89%EF%BC%9A1629%E2%80%931647%EF%BC%8ETANAKA%E2%80%83T%EF%BC%8CWARNER%E2%80%83B%E2%80%83M%EF%BC%8CMICHAEL%E2%80%83D%E2%80%83G%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ALAMP3%E2%80%83inhibits%E2%80%83autophagy%E2%80%83and%E2%80%83contributes%E2%80%83to%E2%80%83cell%E2%80%83death%E2%80%83%0Aby%E2%80%83lysosomal%E2%80%83membrane%E2%80%83permeabilization%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AAutophagy%EF%BC%8C2022%EF%BC%8C18%EF%BC%887%EF%BC%89%EF%BC%9A1629%E2%80%931647%EF%BC%8E
5、FU%E2%80%83B%EF%BC%8CZHOU%E2%80%83M%EF%BC%8CGENG%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8ELAMP3%E2%80%83%20is%E2%80%83%20a%E2%80%83%0Apotent%E2%80%83uterine%E2%80%83corpus%E2%80%83endometrial%E2%80%83carcinoma%E2%80%83prognostic%E2%80%83%0Abiomarker%E2%80%83associated%E2%80%83with%E2%80%83immune%E2%80%83behavior%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AAging%EF%BC%88Albany%E2%80%83NY%EF%BC%89%EF%BC%8C2024%EF%BC%8C16%EF%BC%881%EF%BC%89%EF%BC%9A714-745%EF%BC%8EFU%E2%80%83B%EF%BC%8CZHOU%E2%80%83M%EF%BC%8CGENG%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8ELAMP3%E2%80%83%20is%E2%80%83%20a%E2%80%83%0Apotent%E2%80%83uterine%E2%80%83corpus%E2%80%83endometrial%E2%80%83carcinoma%E2%80%83prognostic%E2%80%83%0Abiomarker%E2%80%83associated%E2%80%83with%E2%80%83immune%E2%80%83behavior%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AAging%EF%BC%88Albany%E2%80%83NY%EF%BC%89%EF%BC%8C2024%EF%BC%8C16%EF%BC%881%EF%BC%89%EF%BC%9A714-745%EF%BC%8E
6、JIANG%E2%80%83G%EF%BC%8CWANG%E2%80%83Y%EF%BC%8EDevelopment%E2%80%83of%E2%80%83endosome%02related%E2%80%83gene%E2%80%83%20signature%E2%80%83for%E2%80%83the%E2%80%83prediction%E2%80%83of%E2%80%83prognosis%E2%80%83%0Aand%E2%80%83therapeutic%E2%80%83response%E2%80%83in%E2%80%83breast%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AMedicine%EF%BC%8C2025%EF%BC%8C104%EF%BC%882%EF%BC%89%EF%BC%9Ae41230%EF%BC%8EJIANG%E2%80%83G%EF%BC%8CWANG%E2%80%83Y%EF%BC%8EDevelopment%E2%80%83of%E2%80%83endosome%02related%E2%80%83gene%E2%80%83%20signature%E2%80%83for%E2%80%83the%E2%80%83prediction%E2%80%83of%E2%80%83prognosis%E2%80%83%0Aand%E2%80%83therapeutic%E2%80%83response%E2%80%83in%E2%80%83breast%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AMedicine%EF%BC%8C2025%EF%BC%8C104%EF%BC%882%EF%BC%89%EF%BC%9Ae41230%EF%BC%8E
7、LIU%E2%80%83J%EF%BC%8CCONG%E2%80%83B%EF%BC%8CCAO%E2%80%83X%EF%BC%8ELung%E2%80%83DC-T%E2%80%83immunity%E2%80%83%0Ahub%E2%80%83in%E2%80%83immune%E2%80%83surveillance%EF%BC%9ANew%E2%80%83concepts%E2%80%83and%E2%80%83future%E2%80%83%0Adirections%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECancer%E2%80%83Commun%EF%BC%88Lond%EF%BC%89%EF%BC%8C2025%EF%BC%8C%0A45%EF%BC%883%EF%BC%89%EF%BC%9A209-214%EF%BC%8ELIU%E2%80%83J%EF%BC%8CCONG%E2%80%83B%EF%BC%8CCAO%E2%80%83X%EF%BC%8ELung%E2%80%83DC-T%E2%80%83immunity%E2%80%83%0Ahub%E2%80%83in%E2%80%83immune%E2%80%83surveillance%EF%BC%9ANew%E2%80%83concepts%E2%80%83and%E2%80%83future%E2%80%83%0Adirections%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECancer%E2%80%83Commun%EF%BC%88Lond%EF%BC%89%EF%BC%8C2025%EF%BC%8C%0A45%EF%BC%883%EF%BC%89%EF%BC%9A209-214%EF%BC%8E
8、NGUYEN%E2%80%83K%EF%BC%8CMITCHELL%E2%80%83B%E2%80%83D%EF%BC%8EA%20%E2%80%83%20g%20ui%20d%20e%20%E2%80%83%20t%20o%E2%80%83%0Aunderstanding%E2%80%83%EF%BC%8Cmendelian%E2%80%83randomization%E2%80%83studies%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EArthritis%E2%80%83Care%E2%80%83Res%EF%BC%88Hoboken%EF%BC%89%EF%BC%8C2024%EF%BC%8C76%0A%EF%BC%8811%EF%BC%89%EF%BC%9A1451-1460%EF%BC%8ENGUYEN%E2%80%83K%EF%BC%8CMITCHELL%E2%80%83B%E2%80%83D%EF%BC%8EA%20%E2%80%83%20g%20ui%20d%20e%20%E2%80%83%20t%20o%E2%80%83%0Aunderstanding%E2%80%83%EF%BC%8Cmendelian%E2%80%83randomization%E2%80%83studies%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EArthritis%E2%80%83Care%E2%80%83Res%EF%BC%88Hoboken%EF%BC%89%EF%BC%8C2024%EF%BC%8C76%0A%EF%BC%8811%EF%BC%89%EF%BC%9A1451-1460%EF%BC%8E
9、CHEN%E2%80%83L%E2%80%83G%EF%BC%8CTUBBS%E2%80%83J%E2%80%83D%EF%BC%8CLIU%E2%80%83Z%EF%BC%8Cet%E2%80%83al%EF%BC%8EMendelian%E2%80%83%0Arandomization%EF%BC%9ACausal%E2%80%83inference%E2%80%83leveraging%E2%80%83genetic%E2%80%83%0Adata%EF%BC%BBJ%EF%BC%BD%EF%BC%8EPsychol%E2%80%83Med%EF%BC%8C2024%EF%BC%8C54%EF%BC%888%EF%BC%89%EF%BC%9A1461-%0A1474%EF%BC%8ECHEN%E2%80%83L%E2%80%83G%EF%BC%8CTUBBS%E2%80%83J%E2%80%83D%EF%BC%8CLIU%E2%80%83Z%EF%BC%8Cet%E2%80%83al%EF%BC%8EMendelian%E2%80%83%0Arandomization%EF%BC%9ACausal%E2%80%83inference%E2%80%83leveraging%E2%80%83genetic%E2%80%83%0Adata%EF%BC%BBJ%EF%BC%BD%EF%BC%8EPsychol%E2%80%83Med%EF%BC%8C2024%EF%BC%8C54%EF%BC%888%EF%BC%89%EF%BC%9A1461-%0A1474%EF%BC%8E
10、KRAFT%E2%80%83P%EF%BC%8CCHEN%E2%80%83H%EF%BC%8CLINDSTR%C3%96M%E2%80%83S%EF%BC%8EThe%E2%80%83%20use%E2%80%83of%E2%80%83%0Agenetic%E2%80%83correlation%E2%80%83and%E2%80%83mendelian%E2%80%83randomization%E2%80%83studies%E2%80%83%0Ato%E2%80%83increase%E2%80%83our%E2%80%83understanding%E2%80%83of%E2%80%83%20relationships%E2%80%83between%E2%80%83%0Acomplex%E2%80%83traits%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECurr%E2%80%83Epidemiol%E2%80%83Rep%EF%BC%8C2020%EF%BC%8C7%0A%EF%BC%882%EF%BC%89%EF%BC%9A104-112%EF%BC%8EKRAFT%E2%80%83P%EF%BC%8CCHEN%E2%80%83H%EF%BC%8CLINDSTR%C3%96M%E2%80%83S%EF%BC%8EThe%E2%80%83%20use%E2%80%83of%E2%80%83%0Agenetic%E2%80%83correlation%E2%80%83and%E2%80%83mendelian%E2%80%83randomization%E2%80%83studies%E2%80%83%0Ato%E2%80%83increase%E2%80%83our%E2%80%83understanding%E2%80%83of%E2%80%83%20relationships%E2%80%83between%E2%80%83%0Acomplex%E2%80%83traits%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECurr%E2%80%83Epidemiol%E2%80%83Rep%EF%BC%8C2020%EF%BC%8C7%0A%EF%BC%882%EF%BC%89%EF%BC%9A104-112%EF%BC%8E
11、LIU%E2%80%83X%EF%BC%8CZHANG%E2%80%83X%EF%BC%8CCHANG%E2%80%83T%EF%BC%8Cet%E2%80%83al%EF%BC%8ECausal%E2%80%83%0Arelationships%E2%80%83between%E2%80%83genetically%E2%80%83predicted%E2%80%83particulate%E2%80%83%0Aair%E2%80%83pollutants%E2%80%83and%E2%80%83neurodegenerative%E2%80%83diseases%EF%BC%9AA%E2%80%83%0Atwo-sample%E2%80%83Mendelian%E2%80%83randomization%E2%80%83study%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AEcotoxicol%E2%80%83Environ%E2%80%83Safy%EF%BC%8C2024%EF%BC%88284%EF%BC%89%EF%BC%9A116960%EF%BC%8ELIU%E2%80%83X%EF%BC%8CZHANG%E2%80%83X%EF%BC%8CCHANG%E2%80%83T%EF%BC%8Cet%E2%80%83al%EF%BC%8ECausal%E2%80%83%0Arelationships%E2%80%83between%E2%80%83genetically%E2%80%83predicted%E2%80%83particulate%E2%80%83%0Aair%E2%80%83pollutants%E2%80%83and%E2%80%83neurodegenerative%E2%80%83diseases%EF%BC%9AA%E2%80%83%0Atwo-sample%E2%80%83Mendelian%E2%80%83randomization%E2%80%83study%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AEcotoxicol%E2%80%83Environ%E2%80%83Safy%EF%BC%8C2024%EF%BC%88284%EF%BC%89%EF%BC%9A116960%EF%BC%8E
12、BAI%E2%80%83Y%EF%BC%8CWANG%E2%80%83X%EF%BC%8CXU%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8EVitamin%E2%80%83D%E2%80%83%20and%E2%80%83%0Agestational%E2%80%83%20diabetes%E2%80%83mellitus%E2%80%83in%E2%80%83the%E2%80%83%20IEU%E2%80%83OpenGWAS%E2%80%83project%EF%BC%9AA%E2%80%83%20two-sample%E2%80%83%20bidirectional%E2%80%83%20mendelian%E2%80%83%0Arandomization%E2%80%83study%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENutrients%EF%BC%8C2024%EF%BC%8C16%0A%EF%BC%8817%EF%BC%89%EF%BC%9A2836%EF%BC%8EBAI%E2%80%83Y%EF%BC%8CWANG%E2%80%83X%EF%BC%8CXU%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8EVitamin%E2%80%83D%E2%80%83%20and%E2%80%83%0Agestational%E2%80%83%20diabetes%E2%80%83mellitus%E2%80%83in%E2%80%83the%E2%80%83%20IEU%E2%80%83OpenGWAS%E2%80%83project%EF%BC%9AA%E2%80%83%20two-sample%E2%80%83%20bidirectional%E2%80%83%20mendelian%E2%80%83%0Arandomization%E2%80%83study%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENutrients%EF%BC%8C2024%EF%BC%8C16%0A%EF%BC%8817%EF%BC%89%EF%BC%9A2836%EF%BC%8E
13、ARTHUR%E2%80%83T%E2%80%83D%EF%BC%8CNGUYEN%E2%80%83J%E2%80%83P%EF%BC%8CHENSON%E2%80%83B%E2%80%83A%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EMultiomic%E2%80%83QTL%E2%80%83mapping%E2%80%83%20reveals%E2%80%83%20phenotypic%E2%80%83%0Acomplexity%E2%80%83%20of%E2%80%83GWAS%E2%80%83loci%E2%80%83%20and%E2%80%83%20prioritizes%E2%80%83%20putative%E2%80%83%0Acausal%E2%80%83variants%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECell%E2%80%83Genom%EF%BC%8C2025%EF%BC%8C5%EF%BC%883%EF%BC%89%EF%BC%9A%0A100775%EF%BC%8EARTHUR%E2%80%83T%E2%80%83D%EF%BC%8CNGUYEN%E2%80%83J%E2%80%83P%EF%BC%8CHENSON%E2%80%83B%E2%80%83A%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EMultiomic%E2%80%83QTL%E2%80%83mapping%E2%80%83%20reveals%E2%80%83%20phenotypic%E2%80%83%0Acomplexity%E2%80%83%20of%E2%80%83GWAS%E2%80%83loci%E2%80%83%20and%E2%80%83%20prioritizes%E2%80%83%20putative%E2%80%83%0Acausal%E2%80%83variants%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECell%E2%80%83Genom%EF%BC%8C2025%EF%BC%8C5%EF%BC%883%EF%BC%89%EF%BC%9A%0A100775%EF%BC%8E
14、%E2%80%83%20SCELO%E2%80%83G%EF%BC%8CPURDUE%E2%80%83M%E2%80%83P%EF%BC%8CBROWN%E2%80%83K%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AGenome-wide%E2%80%83association%E2%80%83study%E2%80%83identifies%E2%80%83multiple%E2%80%83risk%E2%80%83%0Aloci%E2%80%83for%E2%80%83renal%E2%80%83cell%E2%80%83carcinoma%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENat%E2%80%83Commun%EF%BC%8C%0A2017%EF%BC%888%EF%BC%89%EF%BC%9A15724%EF%BC%8E%E2%80%83%20SCELO%E2%80%83G%EF%BC%8CPURDUE%E2%80%83M%E2%80%83P%EF%BC%8CBROWN%E2%80%83K%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AGenome-wide%E2%80%83association%E2%80%83study%E2%80%83identifies%E2%80%83multiple%E2%80%83risk%E2%80%83%0Aloci%E2%80%83for%E2%80%83renal%E2%80%83cell%E2%80%83carcinoma%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENat%E2%80%83Commun%EF%BC%8C%0A2017%EF%BC%888%EF%BC%89%EF%BC%9A15724%EF%BC%8E
15、%E2%80%83%20BOEHM%E2%80%83F%E2%80%83J%EF%BC%8CZHOU%E2%80%83X%EF%BC%8EStatistical%E2%80%83%20methods%E2%80%83%20for%E2%80%83%0AMendelian%E2%80%83%20randomization%E2%80%83in%E2%80%83genome-wide%E2%80%83association%E2%80%83%0Astudies%EF%BC%9AA%E2%80%83review%EF%BC%BBJ%EF%BC%BD%EF%BC%8EComput%E2%80%83%20Struct%E2%80%83Biotechnol%E2%80%83%0AJ%EF%BC%8C2022%EF%BC%8820%EF%BC%89%EF%BC%9A2338-2351%EF%BC%8E%E2%80%83%20BOEHM%E2%80%83F%E2%80%83J%EF%BC%8CZHOU%E2%80%83X%EF%BC%8EStatistical%E2%80%83%20methods%E2%80%83%20for%E2%80%83%0AMendelian%E2%80%83%20randomization%E2%80%83in%E2%80%83genome-wide%E2%80%83association%E2%80%83%0Astudies%EF%BC%9AA%E2%80%83review%EF%BC%BBJ%EF%BC%BD%EF%BC%8EComput%E2%80%83%20Struct%E2%80%83Biotechnol%E2%80%83%0AJ%EF%BC%8C2022%EF%BC%8820%EF%BC%89%EF%BC%9A2338-2351%EF%BC%8E
16、连兴基,彭晓辉,王衍慧,等.调脂药物靶点与高血压肾病风险:一项药物靶向孟德尔随机化分析[J].广州医药,2024,55(8):881-887.连兴基,彭晓辉,王衍慧,等.调脂药物靶点与高血压肾病风险:一项药物靶向孟德尔随机化分析[J].广州医药,2024,55(8):881-887.
17、JIANG%E2%80%83Y%EF%BC%8CCHEN%E2%80%83R%EF%BC%8CXU%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8EEndocrine%E2%80%83and%E2%80%83%0Ametabolic%E2%80%83factors%E2%80%83and%E2%80%83the%E2%80%83%20risk%E2%80%83of%E2%80%83idiopathic%E2%80%83pulmonary%E2%80%83%0Afibrosis%EF%BC%9AA%E2%80%83Mendelian%E2%80%83randomization%E2%80%83study%EF%BC%BBJ%EF%BC%BD%EF%BC%8EFront%E2%80%83%0AEndocrinol%EF%BC%88Lausanne%EF%BC%89%EF%BC%8C2024%EF%BC%8814%EF%BC%89%EF%BC%9A1321576%EF%BC%8EJIANG%E2%80%83Y%EF%BC%8CCHEN%E2%80%83R%EF%BC%8CXU%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8EEndocrine%E2%80%83and%E2%80%83%0Ametabolic%E2%80%83factors%E2%80%83and%E2%80%83the%E2%80%83%20risk%E2%80%83of%E2%80%83idiopathic%E2%80%83pulmonary%E2%80%83%0Afibrosis%EF%BC%9AA%E2%80%83Mendelian%E2%80%83randomization%E2%80%83study%EF%BC%BBJ%EF%BC%BD%EF%BC%8EFront%E2%80%83%0AEndocrinol%EF%BC%88Lausanne%EF%BC%89%EF%BC%8C2024%EF%BC%8814%EF%BC%89%EF%BC%9A1321576%EF%BC%8E
18、HUANG%E2%80%83C%EF%BC%8CLUO%E2%80%83D%EF%BC%8CSUN%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8ENo%E2%80%83%20causal%E2%80%83%0Aassociation%E2%80%83%20between%E2%80%83%20serum%E2%80%83%20vitamin%E2%80%83%20D%E2%80%83%20levels%E2%80%83%20and%E2%80%83%0Adiabetes%E2%80%83retinopathy%EF%BC%9AA%E2%80%83Mendelian%E2%80%83%20randomization%E2%80%83%0Aanalysis%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENutr%E2%80%83Metab%E2%80%83Cardiovasc%E2%80%83Dis%EF%BC%8C2024%EF%BC%8C%0A34%EF%BC%885%EF%BC%89%EF%BC%9A1295-1304%EF%BC%8EHUANG%E2%80%83C%EF%BC%8CLUO%E2%80%83D%EF%BC%8CSUN%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8ENo%E2%80%83%20causal%E2%80%83%0Aassociation%E2%80%83%20between%E2%80%83%20serum%E2%80%83%20vitamin%E2%80%83%20D%E2%80%83%20levels%E2%80%83%20and%E2%80%83%0Adiabetes%E2%80%83retinopathy%EF%BC%9AA%E2%80%83Mendelian%E2%80%83%20randomization%E2%80%83%0Aanalysis%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENutr%E2%80%83Metab%E2%80%83Cardiovasc%E2%80%83Dis%EF%BC%8C2024%EF%BC%8C%0A34%EF%BC%885%EF%BC%89%EF%BC%9A1295-1304%EF%BC%8E
19、BROADBENT%E2%80%83J%E2%80%83R%EF%BC%8CFOLEY%E2%80%83C%E2%80%83N%EF%BC%8CGRANT%E2%80%83A%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AMendelianRandomization%E2%80%83v0%EF%BC%8E5%EF%BC%8E0%EF%BC%9AUpdates%E2%80%83to%E2%80%83an%E2%80%83%0AR%E2%80%83%20package%E2%80%83for%E2%80%83%20performing%E2%80%83Mendelian%E2%80%83%20randomization%E2%80%83%0Aanalyses%E2%80%83using%E2%80%83summarized%E2%80%83data%EF%BC%BBJ%EF%BC%BD%EF%BC%8EWellcome%E2%80%83%0AOpen%E2%80%83Res%EF%BC%8C2020%EF%BC%885%EF%BC%89%EF%BC%9A252%EF%BC%8EBROADBENT%E2%80%83J%E2%80%83R%EF%BC%8CFOLEY%E2%80%83C%E2%80%83N%EF%BC%8CGRANT%E2%80%83A%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AMendelianRandomization%E2%80%83v0%EF%BC%8E5%EF%BC%8E0%EF%BC%9AUpdates%E2%80%83to%E2%80%83an%E2%80%83%0AR%E2%80%83%20package%E2%80%83for%E2%80%83%20performing%E2%80%83Mendelian%E2%80%83%20randomization%E2%80%83%0Aanalyses%E2%80%83using%E2%80%83summarized%E2%80%83data%EF%BC%BBJ%EF%BC%BD%EF%BC%8EWellcome%E2%80%83%0AOpen%E2%80%83Res%EF%BC%8C2020%EF%BC%885%EF%BC%89%EF%BC%9A252%EF%BC%8E
20、%E2%80%83%20FANG%E2%80%83L%EF%BC%8CLIU%E2%80%83Q%EF%BC%8CCUI%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8EBioinformatics%E2%80%83%0Aanalysis%E2%80%83highlight%E2%80%83differentially%E2%80%83expressed%E2%80%83CCNB1%E2%80%83and%E2%80%83%0APLK1%E2%80%83genes%E2%80%83as%E2%80%83potential%E2%80%83anti-breast%E2%80%83cancer%E2%80%83drug%E2%80%83targets%E2%80%83%0Aand%E2%80%83prognostic%E2%80%83markers%EF%BC%BBJ%EF%BC%BD%EF%BC%8EGenes%EF%BC%88Basel%EF%BC%89%EF%BC%8C%0A2022%EF%BC%8C13%EF%BC%884%EF%BC%89%EF%BC%9A654%EF%BC%8E%E2%80%83%20FANG%E2%80%83L%EF%BC%8CLIU%E2%80%83Q%EF%BC%8CCUI%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8EBioinformatics%E2%80%83%0Aanalysis%E2%80%83highlight%E2%80%83differentially%E2%80%83expressed%E2%80%83CCNB1%E2%80%83and%E2%80%83%0APLK1%E2%80%83genes%E2%80%83as%E2%80%83potential%E2%80%83anti-breast%E2%80%83cancer%E2%80%83drug%E2%80%83targets%E2%80%83%0Aand%E2%80%83prognostic%E2%80%83markers%EF%BC%BBJ%EF%BC%BD%EF%BC%8EGenes%EF%BC%88Basel%EF%BC%89%EF%BC%8C%0A2022%EF%BC%8C13%EF%BC%884%EF%BC%89%EF%BC%9A654%EF%BC%8E
21、%E2%80%83%20FENG%E2%80%83X%EF%BC%8CGAO%E2%80%83L%EF%BC%8CSHEN%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8EA%E2%80%83%20pan-cancer%E2%80%83%0Aanalysis%E2%80%83of%E2%80%83prognostic%E2%80%83significance%E2%80%83and%E2%80%83immunological%E2%80%83%0Arole%E2%80%83of%E2%80%83lysosomal-associated%E2%80%83membrane%E2%80%83protein%E2%80%833%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83%0ACell%E2%80%83Mol%E2%80%83Med%EF%BC%8C2024%EF%BC%8C28%EF%BC%883%EF%BC%89%EF%BC%9Ae18088%EF%BC%8E%E2%80%83%20FENG%E2%80%83X%EF%BC%8CGAO%E2%80%83L%EF%BC%8CSHEN%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8EA%E2%80%83%20pan-cancer%E2%80%83%0Aanalysis%E2%80%83of%E2%80%83prognostic%E2%80%83significance%E2%80%83and%E2%80%83immunological%E2%80%83%0Arole%E2%80%83of%E2%80%83lysosomal-associated%E2%80%83membrane%E2%80%83protein%E2%80%833%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83%0ACell%E2%80%83Mol%E2%80%83Med%EF%BC%8C2024%EF%BC%8C28%EF%BC%883%EF%BC%89%EF%BC%9Ae18088%EF%BC%8E
22、WEI%E2%80%83H%EF%BC%8CLI%E2%80%83X%EF%BC%8CLIU%E2%80%83F%EF%BC%8Cet%E2%80%83al%EF%BC%8ECurcumin%E2%80%83inhibits%E2%80%83the%E2%80%83%0Adevelopment%E2%80%83%20of%E2%80%83%20colorectal%E2%80%83%20cancer%E2%80%83%20via%E2%80%83%20regulating%E2%80%83the%E2%80%83%0AUSP4%2FLAMP3%E2%80%83pathway%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENaunyn%E2%80%83Schmiedebergs%E2%80%83%0AArch%E2%80%83Pharmacol%EF%BC%8C2024%EF%BC%8C397%EF%BC%883%EF%BC%89%EF%BC%9A1749-1762%EF%BC%8EWEI%E2%80%83H%EF%BC%8CLI%E2%80%83X%EF%BC%8CLIU%E2%80%83F%EF%BC%8Cet%E2%80%83al%EF%BC%8ECurcumin%E2%80%83inhibits%E2%80%83the%E2%80%83%0Adevelopment%E2%80%83%20of%E2%80%83%20colorectal%E2%80%83%20cancer%E2%80%83%20via%E2%80%83%20regulating%E2%80%83the%E2%80%83%0AUSP4%2FLAMP3%E2%80%83pathway%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENaunyn%E2%80%83Schmiedebergs%E2%80%83%0AArch%E2%80%83Pharmacol%EF%BC%8C2024%EF%BC%8C397%EF%BC%883%EF%BC%89%EF%BC%9A1749-1762%EF%BC%8E
23、TERKELSEN%E2%80%83T%EF%BC%8CRUSSO%E2%80%83F%EF%BC%8CGROMOV%E2%80%83P%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ASecreted%E2%80%83breast%E2%80%83tumor%E2%80%83interstitial%E2%80%83fluid%E2%80%83microRNAs%E2%80%83and%E2%80%83%0Atheir%E2%80%83target%E2%80%83genes%E2%80%83are%E2%80%83associated%E2%80%83with%E2%80%83triple-negative%E2%80%83%0Abreast%E2%80%83cancer%EF%BC%8Ctumor%E2%80%83grade%EF%BC%8Cand%E2%80%83immune%E2%80%83infiltration%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBreast%E2%80%83Cancer%E2%80%83Res%EF%BC%8C2020%EF%BC%8C22%EF%BC%881%EF%BC%89%EF%BC%9A73%EF%BC%8ETERKELSEN%E2%80%83T%EF%BC%8CRUSSO%E2%80%83F%EF%BC%8CGROMOV%E2%80%83P%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ASecreted%E2%80%83breast%E2%80%83tumor%E2%80%83interstitial%E2%80%83fluid%E2%80%83microRNAs%E2%80%83and%E2%80%83%0Atheir%E2%80%83target%E2%80%83genes%E2%80%83are%E2%80%83associated%E2%80%83with%E2%80%83triple-negative%E2%80%83%0Abreast%E2%80%83cancer%EF%BC%8Ctumor%E2%80%83grade%EF%BC%8Cand%E2%80%83immune%E2%80%83infiltration%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBreast%E2%80%83Cancer%E2%80%83Res%EF%BC%8C2020%EF%BC%8C22%EF%BC%881%EF%BC%89%EF%BC%9A73%EF%BC%8E
24、QIU%E2%80%83X%EF%BC%8CYOU%E2%80%83Y%EF%BC%8CHUANG%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8ELAMP3%E2%80%83%20and%E2%80%83%0ATP53%E2%80%83overexpression%E2%80%83predicts%E2%80%83poor%E2%80%83outcome%E2%80%83in%E2%80%83laryngeal%E2%80%83%0Asquamous%E2%80%83cell%E2%80%83carcinoma%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83%20J%E2%80%83%20Clin%E2%80%83%20Exp%E2%80%83%0APathol%EF%BC%8C2015%EF%BC%8C8%EF%BC%885%EF%BC%89%EF%BC%9A5519-5527%EF%BC%8EQIU%E2%80%83X%EF%BC%8CYOU%E2%80%83Y%EF%BC%8CHUANG%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8ELAMP3%E2%80%83%20and%E2%80%83%0ATP53%E2%80%83overexpression%E2%80%83predicts%E2%80%83poor%E2%80%83outcome%E2%80%83in%E2%80%83laryngeal%E2%80%83%0Asquamous%E2%80%83cell%E2%80%83carcinoma%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83%20J%E2%80%83%20Clin%E2%80%83%20Exp%E2%80%83%0APathol%EF%BC%8C2015%EF%BC%8C8%EF%BC%885%EF%BC%89%EF%BC%9A5519-5527%EF%BC%8E
25、LIU%E2%80%83S%EF%BC%8CYUE%E2%80%83J%EF%BC%8CDU%E2%80%83W%EF%BC%8Cet%E2%80%83al%EF%BC%8ELAMP3%E2%80%83%20plays%E2%80%83%20an%E2%80%83%0Aoncogenic%E2%80%83%20role%E2%80%83in%E2%80%83%20osteosarcoma%E2%80%83%20cells%E2%80%83%20partially%E2%80%83%20by%E2%80%83%0Ainhibiting%E2%80%83TP53%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECell%E2%80%83Mol%E2%80%83Biol%E2%80%83Lett%EF%BC%8C2018%0A%EF%BC%8823%EF%BC%89%EF%BC%9A33%EF%BC%8ELIU%E2%80%83S%EF%BC%8CYUE%E2%80%83J%EF%BC%8CDU%E2%80%83W%EF%BC%8Cet%E2%80%83al%EF%BC%8ELAMP3%E2%80%83%20plays%E2%80%83%20an%E2%80%83%0Aoncogenic%E2%80%83%20role%E2%80%83in%E2%80%83%20osteosarcoma%E2%80%83%20cells%E2%80%83%20partially%E2%80%83%20by%E2%80%83%0Ainhibiting%E2%80%83TP53%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECell%E2%80%83Mol%E2%80%83Biol%E2%80%83Lett%EF%BC%8C2018%0A%EF%BC%8823%EF%BC%89%EF%BC%9A33%EF%BC%8E
26、CHEN%E2%80%83Z%EF%BC%8CZHOU%E2%80%83L%EF%BC%8CLIU%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8ESingle-cell%E2%80%83RNA%E2%80%83%0Asequencing%E2%80%83highlights%E2%80%83the%E2%80%83role%E2%80%83of%E2%80%83inflammatory%E2%80%83cancer%02associated%E2%80%83fibroblasts%E2%80%83in%E2%80%83bladder%E2%80%83urothelial%E2%80%83carcinoma%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENat%E2%80%83Commun%EF%BC%8C2020%EF%BC%8C11%EF%BC%881%EF%BC%89%EF%BC%9A5077%EF%BC%8ECHEN%E2%80%83Z%EF%BC%8CZHOU%E2%80%83L%EF%BC%8CLIU%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8ESingle-cell%E2%80%83RNA%E2%80%83%0Asequencing%E2%80%83highlights%E2%80%83the%E2%80%83role%E2%80%83of%E2%80%83inflammatory%E2%80%83cancer%02associated%E2%80%83fibroblasts%E2%80%83in%E2%80%83bladder%E2%80%83urothelial%E2%80%83carcinoma%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENat%E2%80%83Commun%EF%BC%8C2020%EF%BC%8C11%EF%BC%881%EF%BC%89%EF%BC%9A5077%EF%BC%8E
27、TROJANI%E2%80%83M%E2%80%83C%EF%BC%8CSANTUCCI-DARMANIN%E2%80%83S%EF%BC%8C%0ABREUIL%E2%80%83V%EF%BC%8Cet%E2%80%83al%EF%BC%8ELysosomal%E2%80%83exocytosis%EF%BC%9AFrom%E2%80%83%0Acell%E2%80%83protection%E2%80%83to%E2%80%83protumoral%E2%80%83functions%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECancer%E2%80%83%0Aletters%EF%BC%8C2024%EF%BC%88597%EF%BC%89%EF%BC%9A217024%EF%BC%8ETROJANI%E2%80%83M%E2%80%83C%EF%BC%8CSANTUCCI-DARMANIN%E2%80%83S%EF%BC%8C%0ABREUIL%E2%80%83V%EF%BC%8Cet%E2%80%83al%EF%BC%8ELysosomal%E2%80%83exocytosis%EF%BC%9AFrom%E2%80%83%0Acell%E2%80%83protection%E2%80%83to%E2%80%83protumoral%E2%80%83functions%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECancer%E2%80%83%0Aletters%EF%BC%8C2024%EF%BC%88597%EF%BC%89%EF%BC%9A217024%EF%BC%8E
28、PEIRED%E2%80%83A%E2%80%83J%EF%BC%8CCAMPI%E2%80%83R%EF%BC%8CANGELOTTI%E2%80%83M%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8ESex%E2%80%83%0Aand%E2%80%83gender%E2%80%83differences%E2%80%83in%E2%80%83kidney%E2%80%83cancer%EF%BC%9AClinical%E2%80%83and%E2%80%83%0Aexperimental%E2%80%83evidence%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECancers%EF%BC%88Basel%EF%BC%89%EF%BC%8C%0A2021%EF%BC%8C13%EF%BC%8818%EF%BC%89%EF%BC%9A4588%EF%BC%8EPEIRED%E2%80%83A%E2%80%83J%EF%BC%8CCAMPI%E2%80%83R%EF%BC%8CANGELOTTI%E2%80%83M%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8ESex%E2%80%83%0Aand%E2%80%83gender%E2%80%83differences%E2%80%83in%E2%80%83kidney%E2%80%83cancer%EF%BC%9AClinical%E2%80%83and%E2%80%83%0Aexperimental%E2%80%83evidence%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECancers%EF%BC%88Basel%EF%BC%89%EF%BC%8C%0A2021%EF%BC%8C13%EF%BC%8818%EF%BC%89%EF%BC%9A4588%EF%BC%8E
29、LASORSA%E2%80%83F%EF%BC%8CRUTIGLIANO%E2%80%83M%EF%BC%8CMILELLA%E2%80%83M%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8ECellular%E2%80%83%20and%E2%80%83molecular%E2%80%83%20players%E2%80%83in%E2%80%83the%E2%80%83tumor%E2%80%83%0Amicroenvironment%E2%80%83of%E2%80%83renal%E2%80%83cell%E2%80%83carcinoma%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Clin%E2%80%83%0AMed%EF%BC%8C2023%EF%BC%8C12%EF%BC%8812%EF%BC%89%EF%BC%9A3888%EF%BC%8ELASORSA%E2%80%83F%EF%BC%8CRUTIGLIANO%E2%80%83M%EF%BC%8CMILELLA%E2%80%83M%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8ECellular%E2%80%83%20and%E2%80%83molecular%E2%80%83%20players%E2%80%83in%E2%80%83the%E2%80%83tumor%E2%80%83%0Amicroenvironment%E2%80%83of%E2%80%83renal%E2%80%83cell%E2%80%83carcinoma%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Clin%E2%80%83%0AMed%EF%BC%8C2023%EF%BC%8C12%EF%BC%8812%EF%BC%89%EF%BC%9A3888%EF%BC%8E
1、广东省自然粤穗联合青年基金项目(2022A1515111122);广州市科学技术局一般项目(2023A04J0598);广州市卫生健康科技项目(20231A011103)()
上一篇
下一篇
出版者信息








《广州医药》公众号
目录